Table 1.
Patient characteristics of KEYNOTE158 and CheckMate 358.
| / | KEYNOTE-158 [8] | CheckMate 358 [20] |
|---|---|---|
| Treatment | pembrolizumab | nivolumab |
| Phase | II | I/II |
| n | 98 | 19 |
| Stage | ||
| II | 1 (1.0%) | 1 (5.3%) |
| III | 4 (4.1%) | 2 (10.5%) |
| IV | 93 (94.9%) | 16 (84.2%) |
| PD-L1 expression | ||
| Positive | 82 (83.7%) | 10 (62.5%) |
| Negative | 15 (15.3%) | 6 (37.5%) |
| Unknown | 1 (1%) | 3 (15.8%) |
| Previous radiotherapy | 85 (86.7%) | 17 (89.5%) |
| Previous line of systemic therapy | ||
| 0 | 0 (0%) | 0 (0%) |
| 1 | 30 (30.6%) | 8 (42.1%) |
| 2 | 34 (34.7%) | 8 (42.1%) |
| 3 | 16 (16.3%) | 3 (15.8%) |
| Previous antineoplastic agents | ||
| Cisplatin | 79 (80.6%) | 15 (78.9%) |
| Carboplatin | 66 (67.3%) | 11 (57.9%) |
| Paclitaxel | 85 (86.7%) | 12 (63.2%) |
| Bevacizumab | 41 (41.8%) | 6 (31.6%) |
| Topotecan | 17 (17.3%) | 5 (26.3%) |